Cencora, Inc. reported solid fiscal Q2 2026 results with $78.36 billion in sales but fell short of analyst expectations, prompting a cut in full-year revenue growth guidance from 7%-9% to 4%-6%. Despite this, the company raised its adjusted EPS forecast to between $17.65 and $17.90 and announced plans to repurchase $1 billion in stock by year-end. With $2.2 billion in cash reserves, Cencora aims to bolster shareholder value while focusing on operating income growth in its U.S. Healthcare Solutions segment.
“Cencora, Inc. · reported · fiscal 2026 second-quarter results · sales of US$78,355.92 million and net income of US$1,641.33 million”
“Cencora, Inc. · has raised · adjusted EPS outlook · while trimming full-year sales growth guidance”
“Cencora, Inc. · plans to repurchase · US$1 billion of stock · by the end of 2026”
“Cencora, Inc. · maintained · US$0.60 quarterly dividend · at a time when revenue growth guidance has been trimmed”
“Cencora · projects · revenue and earnings by 2029 · $400.7 billion revenue and $3.6 billion earnings”
“Cencora · requires · 7.1% yearly revenue growth · and about a $2.0 billion earnings increase from $1.6 billion today”
“Cencora · beat on earnings in fiscal Q2 · adjusted diluted EPS · up 7.5% to $4.75”
“Cencora · raised full-year adjusted EPS guidance · adjusted EPS · to $17.65-$17.90”
“Cencora · resumed opportunistic share repurchases · stock · plans to buy back $1 billion by year-end”
“Cencora · cut revenue growth guidance · revenue growth · to 4%-6% from 7%-9%”
“Cencora · reported higher fiscal second-quarter adjusted earnings · operating income · increased 6%”
“Cencora · generated adjusted diluted EPS · adjusted diluted EPS · of $4.75”